On March 23, 2026, Oncotelic Therapeutics announced that Sapu Nano, in which it has a minority interest, will present new data on evorlimus toxicology at the Society of Toxicology's Annual Meeting in San Diego. This event is significant for the company as it highlights ongoing research and partnerships.